Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology

Hum Gene Ther. 1992 Jun;3(3):319-38. doi: 10.1089/hum.1992.3.3-319.

Authors

S R Riddell, P D Greenberg, R W Overell, T P Loughran, M J Gilbert, S D Lupton, J Agosti, S Scheeler, R W Coombs, L Corey

PMID: 1643151
DOI: 10.1089/hum.1992.3.3-319

No abstract available

MeSH terms

Adolescent
Adult
Bone Marrow Transplantation*
CD8 Antigens
Clinical Protocols
Combined Modality Therapy
HIV Seropositivity / complications
HIV Seropositivity / drug therapy
HIV Seropositivity / therapy*
Humans
Immunotherapy, Adoptive*
Lymphoma, AIDS-Related / etiology
Lymphoma, AIDS-Related / surgery
Lymphoma, AIDS-Related / therapy*
Middle Aged
T-Lymphocytes, Cytotoxic / immunology
T-Lymphocytes, Cytotoxic / transplantation*
Zidovudine / therapeutic use

Substances

CD8 Antigens
Zidovudine